A.V. Syroeshkin Dr.Sc. (Biol.), Professor, Head of the Department of Pharmaceutical and Toxicological Chemistry, People's Friendship University of Russia (PFUR) (Moscow, Russia) D.A. Galkina Master's student, People's Friendship University of Russia (PFUR) (Moscow, Russia) T.V. Pleteneva Dr.Sc. (Chem.), Professor, People's Friendship University of Russia (PFUR) (Moscow, Russia) M.A. Morozova Ph.D. (Chem.), Associate Professor, People's Friendship University of Russia (PFUR) (Moscow, Russia) O.V. Levitskaya Ph.D. (Chem.), Associate Professor, People's Friendship University of Russia (PFUR) (Moscow, Russia) E-mail:

Relevance. With prolonged use, non-steroidal anti-inflammatory drugs (NSAIDs) cause unwanted side effects. A possible alternative to NSAIDs can be medicines based on non-psychoactive plant cannabinoids, which have successfully proven themselves in the world market. But in the conditions of strict control over the circulation of narcotic drugs in Russian Federation, studies with cannabinoid substances are not possible. Purpose of the study. To characterize the biopharmaceutical parameters of two groups of analgesics using the quantitative structure-activity corre-lation (QSAR) method to demonstrate the advantages of cannabinoids over NSAIDs. Materials and methods. The objects of the study were two groups of analgesics, representatives of the class of NSAIDs and cannabinoids. QSAR method was used. Results. It was shown that the calculated Wiener (W) and Balaban (J) topological indices are in one-to-one correspondence with such biopharmaceuti-cal parameters as equilibrium binding constants with CB1 and CB2 cannabinoid receptors, toxicity (LD50, mice/rat, per os), lipophilicity (logP). The LD50-W/J and logP-W/J diagrams clearly demonstrate that cannabinoids have higher lipophilicity and lower toxicity compared to NSAIDs. Conclusions. The results obtained open prospects for replacing NSAIDs with analgesic cannabinoid preparations and make it possible to recommend the approaches for assessing the toxicity and lipophilicity of new plant cannabinoids and their synthetic analogues.

QSAR modeling
Wiener and Balaban topological indices

  1. Ho Kok Yuen, Cardosa Mary S., Chaiamnuay Sumapa, et al. Prac-tice Advisory on the NSAIDs in Primary Care. Journal of Pain Re-search. 2020; 13: 1925–1939.
  2. Freo U., Ruocco C., Vale rio A., et al. Paracetamol: A Review of Guideline Recommendations. Journal of Clinical Medicine. 2021; 10: 3420. doi:10.3390/jcm10153420.
  3. Überall M.A. A Review of Scientific Evidence for THC: CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain. Journal of Pain Research. 2020; 13: 399-410. doi: 10.2147/JPR.S240011.
  4. Salami Seyed Alireza, Martinelli Federico, Giovino Antonio, et al. It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. Molecules. 2020; 25: 4036.
  5. doi: 10.3390/molecules25184036.
  6. Urits Ivan, Borchart Matthew, Hasegawa Morgan, et al. An Up-date of Current Cannabis-Based Pharmaceuticals in Pain Medicine. Pain and Therapy. 2019. doi: 10.1007/s40122-019-0114-4.
  7. Khan A.U. Descriptors and their selection methods in QSAR analy-sis: paradigm for drug design. Drug Discov. Today. 2016; 21: 1291-1302. doi: 10.1016/j.drudis.2016.06.013.
  8. Mc Partland J.M., Glass M., Pertwee R.G. Meta-analysis of canna-binoid ligand binding affinity and receptor distribution: interspecies differences. British Journal of Pharmacology. 2007; 152: 583-593. doi: 10.1038/sj.bjp.0707399.
  9. Preedy V.R. (Ed.) Handbook of Cannabis and Related Pathologies. Biology, Pharmacology, Diagnosis and Treatment/ Elsevier Sci-ence. 2016; 1170 p.
  10. Shafi A., Berry A. J., Sumnall H., et al. New psychoactive sub-stances: a review and updates. Therapeutic Advances in Psycho-pharmacology. 2020; doi: 10.1177/2045125320967197.